Calidi Biotherapeutics Inc (CLDI)
0.235
-0.01
(-5.28%)
USD |
NYAM |
May 21, 16:00
0.235
0.00 (0.00%)
After-Hours: 17:06
Calidi Biotherapeutics SG&A Expense (Quarterly): 4.009M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 4.009M |
December 31, 2023 | 5.862M |
September 30, 2023 | 3.97M |
March 31, 2023 | 2.792M |
Date | Value |
---|---|
December 31, 2022 | 2.425M |
September 30, 2022 | 5.041M |
December 31, 2021 | 1.945M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.945M
Minimum
Dec 2021
5.862M
Maximum
Dec 2023
3.721M
Average
3.97M
Median
Sep 2023
SG&A Expense (Quarterly) Benchmarks
Minerva Neurosciences Inc | 2.515M |
Viking Therapeutics Inc | 9.97M |
CytomX Therapeutics Inc | 7.754M |
Genprex Inc | 2.720M |
Janux Therapeutics Inc | 7.343M |